Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations

Chen Shi, Yu Zhang|Acta Pharmaceutica Sinica B|2023

Cited by 10